Methods and compositions for enhancing engraftment of hematopoietic stem cells
The present disclosure relates to the field of hematopoietic stem cell transplantation. More specifically, methods, compositions and kits for improving engraftment of stem cell transplants by administering myeloid progenitor cells are provided.
1. A method of enhancing engraftment of an allogeneic hematopoietic stem cell (HSC) graft in a patient, comprising administering the HSC graft to said patient at a suboptimal dose in conjunction with an expanded allogeneic myeloid progenitor (MP) cell graft comprising common myeloid progenitor (CMP) cells, granulocyte/macrophage progenitor (GMP) cells, and megakaryocyte/erythroid progenitor (MEP) cells in an amount effective to enhance the engraftment of the hematopoietic stem cells, wherein the myeloid progenitor cell graft comprises a population of pooled, culture-expanded, myeloid progenitor cells from multiple unrelated donors, wherein the MP cell graft enhances engraftment of the HSC graft suboptimal dose, thereby enhancing engraftment of the HSC graft.
2. The method of claim 1 , wherein the suboptimal HSC graft comprises less than 5.0×10 6 CD34 + hematopoietic stem cells (HSCs) per kg patient body weight.
3. The method of claim 1 , wherein the suboptimal HSC graft comprises less than 1.0×10 6 CD34 + HSCs per kg patient body weight.
4. The method of claim 1 , wherein the suboptimal HSC graft is obtained from peripheral blood or bone marrow.
5. The method of claim 1 , wherein the suboptimal HSC graft is obtained from umbilical cord blood (UBC).
6. The method of claim 5 , wherein the suboptimal HSC graft comprises less than 4×10 7 nucleated cells per kg patient body weight.
7. The method of claim 5 , wherein the suboptimal HSC graft comprises less than 4.0×10 5 CD34 + cells per kg patient body weight.
8. The method of claim 5 , wherein the suboptimal HSC graft comprises HSCs obtained from less than two cord blood units.
9. The method of claim 5 , wherein the suboptimal HSC graft comprises HSCs obtained from a single cord blood unit.
10. The method of claim 1 , wherein said allogeneic MP cell graft and said HSC graft are at least partially mismatched at the major histocompatability complex (MHC) with respect to the patient.
11. The method of claim 1 , wherein said myeloid progenitor cell graft is administered concurrently with said hematopoietic stem cell graft.
12. The method of claim 1 , wherein said myeloid progenitor cell graft is administered within 12 hours of said hematopoietic stem cell graft.
13. The method of claim 1 , wherein said allogeneic myeloid progenitor cells are at least partially mismatched at the major histocompatability complex (MHC) with respect to the hematopoietic stem cell graft.